This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, H.
Right arrow Articles by Kim, K.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, H.
Right arrow Articles by Kim, K.-H.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, March 2009, p. 376-381, Vol. 16, No. 3
1071-412X/09/$08.00+0     doi:10.1128/CVI.00344-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Immune Response in Infants to the Heptavalent Pneumococcal Conjugate Vaccine against Vaccine-Related Serotypes 6A and 19A {triangledown}

Hyunju Lee,1,2 Moon H. Nahm,3 Robert Burton,3 and Kyung-Hyo Kim1,2*

Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Republic of Korea,1 Center for Vaccine Evaluation and Study, Ewha Medical Research Institute, Ewha Womans University, Seoul, Republic of Korea,2 Departments of Pathology and Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 352943

Received 19 September 2008/ Returned for modification 26 November 2008/ Accepted 6 January 2009

The currently available 7-valent pneumococcal conjugate vaccine (PCV7) elicits good immune response to and is effective against vaccine serotypes. However, its effectiveness against vaccine-related serotypes is variable. Serum samples were obtained 1 month after the last vaccination from 31 infants immunized with PCV7 at 2, 4, and 6 months of age. The sera were used to determine immunoglobulin G antibody levels to eight serotypes (seven vaccine serotypes and serotype 19A) with enzyme-linked immunosorbent assay (ELISA) and opsonic capacity against 11 serotypes (seven vaccine serotypes, serotypes 19A and 6A, and nonvaccine serotypes 5 and 7F) using a multiplexed opsonization assay. ELISA results showed antibody concentrations varied between 1.84 and 10.49 µg/ml, and all subjects had antibody concentrations of ≥0.35 µg/ml for all serotypes, including serotype 19A. In contrast, the opsonic index was detectable (i.e., opsonic index ≥ 8) in all children for the seven vaccine serotypes, 81% for serotype 6A, and merely 19% for serotype 19A. PCV7 shows good immunogenicity for vaccine serotypes in infants after a primary series. PCV7 does not elicit opsonic antibodies to serotype 19A. ELISA may thus be an inadequate surrogate assay for evaluating the response for cross-reactive serotypes in infants.

* Corresponding author. Mailing address: Department of Pediatrics, Ewha Womans University Mokdong Hospital, 911-1 Mokdong Yangcheon-Ku, Seoul 158-710, Republic of Korea. Phone: 82-2-2650-2857. Fax: 82-2-2650-2817. E-mail: kaykim{at}ewha.ac.kr

{triangledown} Published ahead of print on 14 January 2009.

Clinical and Vaccine Immunology, March 2009, p. 376-381, Vol. 16, No. 3
1071-412X/09/$08.00+0     doi:10.1128/CVI.00344-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»